Drugs / Ultrix Quadri
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2/3 | NCT05869201 Comparator | Oct → Dec 2020 | influenza | St. Petersburg Research Institute of Vaccines and Sera | Completed | No outcome recorded |
| Phase 4 | NCT05232292 Comparator | Oct 2021 → Dec 2022 | acute coronary syndrome, heart failure | Samara Regional Cardiology Dispensary | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ultrix Quadri | “The goal of this clinical trial is to assess tolerability, safety and immunogenicity of the Flu-M Quadro vaccine as compared to the Ultrix® Quadri vaccine in volunteers aged...” NCT05869201 ↗ |
| Modality | Vaccine | “Experimental Drug: influenza vaccine Ultrix Quadri” NCT05232292 ↗ |
| Route | Subcutaneous | “Standard influenza vaccine administered as a deep subcutaneous injection at one occasion per subject.” NCT05232292 ↗ |